Olivier Aubert

List of Publications by Year
in descending order

41 papers	**2,732** citations	257450 **24** h-index	361022 **35** g-index
43 all docs	**43** docs citations	**43** times ranked	**3416** citing authors

#	Article	IF	Citations
1	FC 114: Monoclonal Gammopathy in Kidney Transplanted Patients: Novel Insights into Long-Term Outcomes. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
2	MO1021: Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
3	FC 105: Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
4	Trajectories of glomerular filtration rate and progression to end stage kidney disease afterÂkidney transplantation. Kidney International, 2021, 99, 186-197.	5.2	40
5	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. American Journal of Transplantation, 2021, 21, 1285-1294.	4.7	69
6	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. American Journal of Transplantation, 2021, 21, 2448-2458.	4.7	31
7	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. Journal of the American Society of Nephrology: JASN, 2021, 32, 397-409.	6.1	40
8	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. Journal of the American Society of Nephrology: JASN, 2021, 32, 1084-1096.	6.1	28
9	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2021, 32, 1264-1265.	6.1	0
10	A kidney discard decision strategy based on zeroâ€time histology analysis could lead to an unjustified increase in the organ turndown rate among ECD. Transplant International, 2021, 34, 1506-1516.	1.6	1
11	COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health, The, 2021, 6, e709-e719.	10.0	139
12	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open, 2021, 11, e052138.	1.9	24
13	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. The Lancet Digital Health, 2021, 3, e795-e805.	12.3	25
14	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. American Journal of Transplantation, 2020, 20, 1365-1374.	4.7	20
15	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. Transplantation, 2020, 104, 2625-2631.	1.0	15
16	Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation. Circulation, 2020, 141, 1954-1967.	1.6	50
17	Organ procurement and transplantation during the COVID-19 pandemic. Lancet, The, 2020, 395, e95-e96.	13.7	222
18	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	1.6	12

#	Article	IF	Citations
19	The Number of Discarded Kidneys Is Likely Much Larger Than Reportedâ€"Reply. JAMA Internal Medicine, 2020, 180, 467.	5.1	0
20	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. JAMA Internal Medicine, 2019, 179, 1365.	5.1	125
21	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, l4923.	2.3	191
22	Towards a precision medicine approach to positive crossmatch transplantation: Impact on response to therapy. American Journal of Transplantation, 2019, 19, 1611-1613.	4.7	1
23	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney International, 2019, 96, 189-201.	5.2	117
24	Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival. Journal of the American Society of Nephrology: JASN, 2019, 30, 625-639.	6.1	48
25	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cellâ€"mediated rejection. American Journal of Transplantation, 2019, 19, 1972-1988.	4.7	60
26	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. Nephrology Dialysis Transplantation, 2019, 34, 1597-1604.	0.7	2
27	Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival. Journal of the American Society of Nephrology: JASN, 2018, 29, 1761-1770.	6.1	36
28	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. Journal of the American Society of Nephrology: JASN, 2018, 29, 620-635.	6.1	94
29	T cellâ€"mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. American Journal of Transplantation, 2018, 18, 377-390.	4.7	76
30	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney International, 2018, 94, 773-787.	5.2	38
31	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLoS Medicine, 2018, 15, e1002572.	8.4	76
32	Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection. Circulation, 2017, 135, 917-935.	1.6	139
33	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 1912-1923.	6.1	208
34	Value of Donorâ€"Specific Antiâ€"HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. Journal of the American Society of Nephrology: JASN, 2017, 28, 702-715.	6.1	111
35	Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. Transplant International, 2016, 29, 1205-1215.	1.6	7
36	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. Journal of the American Society of Nephrology: JASN, 2016, 27, 293-304.	6.1	244

#	Article	IF	Citations
37	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ, The, 2015, 351, h3557.	6.0	146
38	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2015, 26, 1721-1731.	6.1	243
39	Determinants and Outcomes of Accelerated Arteriosclerosis. Circulation Research, 2015, 117, 470-482.	4.5	41
40	Autoimmune Neutropenia After Kidney Transplantation. Transplantation, 2014, 97, 725-729.	1.0	5
41	The Case	Post-tranplant allograft dysfunction. Kidney International, 2013, 83, 765-767.	5.2	8